Literature DB >> 18812762

The value-based medicine comparative effectiveness and cost-effectiveness of penetrating keratoplasty for keratoconus.

Richard H Roe1, Jonathan H Lass, Gary C Brown, Melissa M Brown.   

Abstract

OBJECTIVE: To perform a base case, comparative effectiveness, and cost-effectiveness (cost-utility) analysis of penetrating keratoplasty for patients with severe keratoconus.
METHODS: Visual acuity data were obtained from a large, retrospective multicenter study in which patients with keratoconus with less than 20/40 best corrected visual acuity and/or the inability to wear contact lenses underwent penetrating keratoplasty, with an average follow-up of 2.1 years. The results were combined with other retrospective studies investigating complication rates of penetrating keratoplasty. The data were then incorporated into a cost-utility model using patient preference-based, time trade-off utilities, computer-based decision analysis, and a net present value model to account for the time value of outcomes and money. The comparative effectiveness of the intervention is expressed in quality-of-life gain and QALYs (quality-adjusted life-years), and the cost-effectiveness results are expressed in the outcome of $/QALY (dollars spent per QALY).
RESULTS: Penetrating keratoplasty in 1 eye for patients with severe keratoconus results in a comparative effectiveness (value gain) of 16.5% improvement in quality of life every day over the 44-year life expectancy of the average patient with severe keratoconus. Discounting the total value gain of 5.36 QALYs at a 3% annual discount rate yields 3.05 QALYs gained. The incremental cost for penetrating keratoplasty, including all complications, is $5934 ($5913 discounted at 3% per year). Thus, the incremental cost-utility (discounted at 3% annually) for this intervention is $5913/3.05 QALYs = $1942/QALY. If both eyes undergo corneal transplant, the total discounted value gain is 30% and the overall cost-utility is $2003. Surgery on the second eye confers a total discounted value gain of 2.5 QALYs, yielding a quality-of-life gain of 11.6% and a discounted cost-utility of $2238/QALY.
CONCLUSIONS: Penetrating keratoplasty for patients with severe keratoconus seems to be a comparatively effective and cost-effective procedure when compared with other interventions across different medical specialties.

Entities:  

Mesh:

Year:  2008        PMID: 18812762     DOI: 10.1097/ICO.0b013e31817bb062

Source DB:  PubMed          Journal:  Cornea        ISSN: 0277-3740            Impact factor:   2.651


  3 in total

Review 1.  New clinical pathways for keratoconus.

Authors:  D M Gore; A J Shortt; B D Allan
Journal:  Eye (Lond)       Date:  2012-12-21       Impact factor: 3.775

2.  Descemet membrane endothelial keratoplasty (DMEK) improves vision-related quality of life.

Authors:  Alexandra Gellert; Jan Darius Unterlauft; Matus Rehak; Christian Girbardt
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2022-05-25       Impact factor: 3.535

3.  Value-Based Model: A New Perspective in Medical Decision-making.

Authors:  Silvia Riva; Gabriella Pravettoni
Journal:  Front Public Health       Date:  2016-06-13
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.